Cargando…

Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration

INTRODUCTION: Reduced concentrations of placental protein 13 (PP13) during the first trimester of human pregnancy are associated with elevated risk for the subsequent development of preeclampsia, which is one of the deadliest obstetrical complications of pregnancy. Previous studies by our group have...

Descripción completa

Detalles Bibliográficos
Autores principales: Drobnjak, Tijana, Jónsdóttir, Anna Margrét, Helgadóttir, Helga, Runólfsdóttir, Margrét Soffía, Meiri, Hamutal, Sammar, Marei, Osol, George, Mandalà, Maurizio, Huppertz, Berthold, Gizurarson, Sveinbjörn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443218/
https://www.ncbi.nlm.nih.gov/pubmed/30988643
http://dx.doi.org/10.2147/IJWH.S188303
_version_ 1783407826063851520
author Drobnjak, Tijana
Jónsdóttir, Anna Margrét
Helgadóttir, Helga
Runólfsdóttir, Margrét Soffía
Meiri, Hamutal
Sammar, Marei
Osol, George
Mandalà, Maurizio
Huppertz, Berthold
Gizurarson, Sveinbjörn
author_facet Drobnjak, Tijana
Jónsdóttir, Anna Margrét
Helgadóttir, Helga
Runólfsdóttir, Margrét Soffía
Meiri, Hamutal
Sammar, Marei
Osol, George
Mandalà, Maurizio
Huppertz, Berthold
Gizurarson, Sveinbjörn
author_sort Drobnjak, Tijana
collection PubMed
description INTRODUCTION: Reduced concentrations of placental protein 13 (PP13) during the first trimester of human pregnancy are associated with elevated risk for the subsequent development of preeclampsia, which is one of the deadliest obstetrical complications of pregnancy. Previous studies by our group have shown that PP13 lowers blood pressure in pregnant rats, increases the size and weight of pups and placentas, and induces vasodilation of resistance arteries through endothelial signaling pathways involving endothelial nitric oxid synthase and prostaglandin. METHODS: In the present study, the effect of PP13 was investigated in nonpregnant female Sprague Dawley rats (n=27). Osmotic pumps were surgically implanted subcutaneously that released a constant dose of PP13 or saline over 7 days. Most animals were sacrificed 6 days after the end of PP13 release (on day 13), while some were sacrificed immediately at the end of day 7 (the last PP13 release day), to compare the short- and long-term impact of PP13 on vessels’ growth and size. RESULTS: The uterine vessels were significantly expanded in the group exposed to recombinant PP13 (rPP13) compared to the control (saline) group. Both veins and arteries were significantly expanded by rPP13 with a more pronounced effect after 13 days compared to the corresponding vessels after 7 days. Furthermore, the long-term effect of treatment by rPP13 was more pronounced in the veins compared to the corresponding arteries. The effect of a PP13 variant with a histidine-tag (His-PP13) remained the same between 7 and 13 days. CONCLUSION: In conclusion, PP13 might play a key role in the expansive remodeling of the uterine vessels, reflecting what would happen if the rat was pregnant, preparing the uterine vascu-lature for the increase in uteroplacental blood flow, which is necessary for normal pregnancy. We suggest that PP13 could act by NO signaling pathways, a hypothesis that requires future study.
format Online
Article
Text
id pubmed-6443218
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-64432182019-04-15 Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration Drobnjak, Tijana Jónsdóttir, Anna Margrét Helgadóttir, Helga Runólfsdóttir, Margrét Soffía Meiri, Hamutal Sammar, Marei Osol, George Mandalà, Maurizio Huppertz, Berthold Gizurarson, Sveinbjörn Int J Womens Health Original Research INTRODUCTION: Reduced concentrations of placental protein 13 (PP13) during the first trimester of human pregnancy are associated with elevated risk for the subsequent development of preeclampsia, which is one of the deadliest obstetrical complications of pregnancy. Previous studies by our group have shown that PP13 lowers blood pressure in pregnant rats, increases the size and weight of pups and placentas, and induces vasodilation of resistance arteries through endothelial signaling pathways involving endothelial nitric oxid synthase and prostaglandin. METHODS: In the present study, the effect of PP13 was investigated in nonpregnant female Sprague Dawley rats (n=27). Osmotic pumps were surgically implanted subcutaneously that released a constant dose of PP13 or saline over 7 days. Most animals were sacrificed 6 days after the end of PP13 release (on day 13), while some were sacrificed immediately at the end of day 7 (the last PP13 release day), to compare the short- and long-term impact of PP13 on vessels’ growth and size. RESULTS: The uterine vessels were significantly expanded in the group exposed to recombinant PP13 (rPP13) compared to the control (saline) group. Both veins and arteries were significantly expanded by rPP13 with a more pronounced effect after 13 days compared to the corresponding vessels after 7 days. Furthermore, the long-term effect of treatment by rPP13 was more pronounced in the veins compared to the corresponding arteries. The effect of a PP13 variant with a histidine-tag (His-PP13) remained the same between 7 and 13 days. CONCLUSION: In conclusion, PP13 might play a key role in the expansive remodeling of the uterine vessels, reflecting what would happen if the rat was pregnant, preparing the uterine vascu-lature for the increase in uteroplacental blood flow, which is necessary for normal pregnancy. We suggest that PP13 could act by NO signaling pathways, a hypothesis that requires future study. Dove Medical Press 2019-03-27 /pmc/articles/PMC6443218/ /pubmed/30988643 http://dx.doi.org/10.2147/IJWH.S188303 Text en © 2019 Drobnjak et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Drobnjak, Tijana
Jónsdóttir, Anna Margrét
Helgadóttir, Helga
Runólfsdóttir, Margrét Soffía
Meiri, Hamutal
Sammar, Marei
Osol, George
Mandalà, Maurizio
Huppertz, Berthold
Gizurarson, Sveinbjörn
Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration
title Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration
title_full Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration
title_fullStr Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration
title_full_unstemmed Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration
title_short Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration
title_sort placental protein 13 (pp13) stimulates rat uterine vessels after slow subcutaneous administration
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443218/
https://www.ncbi.nlm.nih.gov/pubmed/30988643
http://dx.doi.org/10.2147/IJWH.S188303
work_keys_str_mv AT drobnjaktijana placentalprotein13pp13stimulatesratuterinevesselsafterslowsubcutaneousadministration
AT jonsdottirannamargret placentalprotein13pp13stimulatesratuterinevesselsafterslowsubcutaneousadministration
AT helgadottirhelga placentalprotein13pp13stimulatesratuterinevesselsafterslowsubcutaneousadministration
AT runolfsdottirmargretsoffia placentalprotein13pp13stimulatesratuterinevesselsafterslowsubcutaneousadministration
AT meirihamutal placentalprotein13pp13stimulatesratuterinevesselsafterslowsubcutaneousadministration
AT sammarmarei placentalprotein13pp13stimulatesratuterinevesselsafterslowsubcutaneousadministration
AT osolgeorge placentalprotein13pp13stimulatesratuterinevesselsafterslowsubcutaneousadministration
AT mandalamaurizio placentalprotein13pp13stimulatesratuterinevesselsafterslowsubcutaneousadministration
AT huppertzberthold placentalprotein13pp13stimulatesratuterinevesselsafterslowsubcutaneousadministration
AT gizurarsonsveinbjorn placentalprotein13pp13stimulatesratuterinevesselsafterslowsubcutaneousadministration